QTTB
$6.68+0.01 (+0.15%)
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (A...
Recent News
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for March 19th
FIGS, QTTB and NESR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 19, 2026.
New Strong Buy Stocks for March 19th
FIGS, QTTB, ORN, FIX and PIPR have been added to the Zacks Rank #1 (Strong Buy) List on March 19, 2026.
Best Momentum Stocks to Buy for March 13th
QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.